NCT06474533Recruiting
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 199 (estimated)
- First submitted
- 19 Jun 2024
- Start date
- 21 Jun 2024
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- Thomas Hope
- Diseases
- Childhood cancers
- NCT number
- NCT06474533
What you commit to
- Study type: Observational
- Planned participants: 199
- From 21 Jun 2024 to the primary completion date, 31 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
- Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.
- Sedation or anesthesia can be used for participants who cannot tolerate the exam.
Who the study is looking for
- Presence or suspicion of intracranial neoplasm in two populations:
- Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
- Three sub-populations will be considered:
- Recurrent metastatic lesions.
- Recurrent high-grade gliomas (Grades 3 and 4).
- Recurrent low-grade gliomas (Grade 2).
- Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.
- Age \> 3 years.
- Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.
Age in the registry: 4 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.